
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(Amendment No. 3)*

Keenova Therapeutics plc

(Name of Issuer)

Ordinary Shares, par value \$0.01 per share

(Title of Class of Securities)

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
 Rule 13d-1(c)
 Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

MARATHON ASSET MANAGEMENT GP, L.L.C.

Check the appropriate box if a member of a Group (see instructions)

2

- (a)
 (b)

3

Sec Use Only

Citizenship or Place of Organization

4

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power
	0.00	
		Shared Voting Power
	6	
	2,710,229.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	2,710,229.00	
		Aggregate Amount Beneficially Owned by Each Reporting Person
9	2,710,229.00	
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
	<input type="checkbox"/>	
11		Percent of class represented by amount in row (9)
	6.8 %	
12		Type of Reporting Person (See Instructions)
	OO	

Comment for Type of Reporting Person: See item 2 for additional information.

SCHEDULE 13G

CUSIP No.

1		Names of Reporting Persons
		MARATHON ASSET MANAGEMENT, L.P.
		Check the appropriate box if a member of a Group (see instructions)
2	<input type="checkbox"/>	(a)
	<input type="checkbox"/>	(b)
3		Sec Use Only
4		Citizenship or Place of Organization
		DELAWARE
		Sole Voting Power
	5	
	0.00	
Number of Shares Beneficially Owned by Each Reporting Person With:		Shared Voting Power
	6	
	2,710,229.00	
		Sole Dispositive Power
	7	
	0.00	
		Shared Dispositive Power
	8	
	2,710,229.00	
		Aggregate Amount Beneficially Owned by Each Reporting Person
9	2,710,229.00	
10		Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)



Percent of class represented by amount in row (9)

11

6.8 %

Type of Reporting Person (See Instructions)

12

PN

Comment for Type of Reporting Person: See item 2 for additional information.

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

BRUCE RICHARDS

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

Beneficially
Owned by

6

2,710,229.00

Each
Reporting

7

0.00

Person

Shared Dispositive

With:

8

Power

2,710,229.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

2,710,229.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10



Percent of class represented by amount in row (9)

11

6.8 %

Type of Reporting Person (See Instructions)

12

IN

Comment for Type of Reporting Person: See item 2 for additional information.

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

1

LOUIS HANOVER

Check the appropriate box if a member of a Group (see instructions)

2

(a)

(b)

3

Sec Use Only

Citizenship or Place of Organization

4

UNITED STATES

Sole Voting Power

5

0.00

Number of
Shares

Shared Voting Power

6

2,710,229.00

Beneficially
Owned by
Each

Sole Dispositive Power

7

0.00

Reporting
Person

Shared Dispositive

With:

Power

8

2,710,229.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9

2,710,229.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

10

Percent of class represented by amount in row (9)

11

6.8 %

Type of Reporting Person (See Instructions)

12

IN

Comment for Type of Reporting Person: See item 2 for additional information.

SCHEDULE 13G

Item 1.

Name of issuer:

(a)

Keenova Therapeutics plc

Address of issuer's principal executive offices:

(b)

College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland

Item 2.

(a)

Name of person filing:

This statement is filed by the following Reporting Persons: (i) Marathon Asset Management GP, L.L.C., a Delaware limited liability company ("Marathon GP"), the general partner of Marathon; (ii) Marathon Asset Management, L.P., a Delaware limited partnership ("Marathon"); (iii) Bruce Richards, a managing member of Marathon GP; and (iv) Louis Hanover, a managing member of Marathon GP. Information with respect to each of the Reporting Persons is given solely by such Reporting Person, and no Reporting Person assumes responsibility for the accuracy or completeness of information by another Reporting Person. Marathon, pursuant to certain investment management agreements and in its capacity as the investment manager of each of the Marathon Funds, has the sole power to vote and the sole power to direct the disposition of all ordinary shares, par value \$0.01 per share (the "Ordinary Shares"),

held by the Marathon Funds. Accordingly, for the purposes of Section 240.13d-3 of the Exchange Act, Marathon may be deemed to beneficially own the Ordinary Shares held by the Marathon Funds. The general partner of Marathon is Marathon GP. Bruce Richards and Louis Hanover are the managing members of Marathon GP. This report shall not be deemed an admission that Marathon, each Marathon Fund or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Exchange Act or for any other purpose. The following ceased being Reporting Persons as of November 14, 2025 pursuant to that certain Schedule 13G Amendment No. 2 filed with the Securities and Exchange Commission on November 14, 2025: (i) Marathon Blue Grass Credit Fund, LP, a Delaware limited partnership; (ii) Marathon Centre Street Partnership, L.P., a Delaware limited partnership; (iii) Marathon StepStone Master Fund LP, a Cayman Islands limited partnership; (iv) MCSP Sub LLC, a Delaware limited liability company; (v) Quaestio Alternative Funds S.C.A., SICAV-FIS: CMAB - SIF - Credit Multi Asset Pool B, a Luxembourg Societe d'Investissement a Capital Variable; (vi) TRS Credit Fund, LP, a Delaware limited partnership; (vii) MDCF II Investment Fund A SCSp, a Luxembourg special limited partnership; (viii) Marathon Distressed Credit Fund, L.P., a Delaware limited partnership; and (ix) Marathon Special Opportunity Master Fund Ltd, a Cayman Islands limited company.

Address or principal business office or, if none, residence:

- (b) The principal business and principal office address of the Reporting Persons is c/o Marathon Asset Management, L.P., 1 Bryant Park, 38th Floor, New York, NY 10036.

Citizenship:

- (c) Marathon GP and Marathon are organized under the laws of the State of Delaware. Mr. Richards and Mr. Hanover are citizens of the United States.

Title of class of securities:

- (d) Ordinary Shares, par value \$0.01 per share

- (e) CUSIP No.:

Item 4. Ownership

Amount beneficially owned:

- (a) Marathon GP; Marathon; Mr. Richards; and Mr. Hanover - 2,710,229.00

Percent of class:

- (b) Marathon GP; Marathon; Mr. Richards; and Mr. Hanover - 6.8% %

- (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

0.00

(ii) Shared power to vote or to direct the vote:

Marathon GP; Marathon; Mr. Richards; and Mr. Hanover - 2,710,229.00

(iii) Sole power to dispose or to direct the disposition of:

0.00

(iv) Shared power to dispose or to direct the disposition of:

Marathon GP; Marathon; Mr. Richards; and Mr. Hanover - 2,710,229.00

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

MARATHON ASSET MANAGEMENT GP, L.L.C.

Signature: /s/ Anne Campbell

Name/Title: Anne Campbell/Authorized Signatory

Date: 05/15/2026

MARATHON ASSET MANAGEMENT, L.P.

Signature: /s/ Anne Campbell

Anne Campbell, Authorized Signatory for
Name/Title: Marathon Asset Management GP, L.L.C., its
general partner

Date: 05/15/2026

BRUCE RICHARDS

Signature: /s/ Anne Campbell

Name/Title: Anne Campbell/Authorized Signatory

Date: 05/15/2026

LOUIS HANOVER

Signature: /s/ Anne Campbell

Name/Title: Anne Campbell/Authorized Signatory

Date: 05/15/2026

Exhibit Information

99.2 - Joint Filing Agreement, dated as of November 14, 2025, among the Reporting Persons.